Navigation Links
New Gene for Lou Gehrig's Disease Identified
Date:2/28/2008

Rare TDP-43 mutations expose potential therapeutic target, experts say

THURSDAY, Feb. 28 (HealthDay News) -- Researchers have implicated a new, yet rare, genetic mutation in the development of amyotrophic lateral sclerosis (ALS).

The finding not only exposes a potential therapeutic target for treating the fatal neurodegenerative disease, it also confirms that this particular mutation sets in motion the mechanism that causes many cases of ALS.

The results provide "a link between genetics and [the] pathology that proves that the pathology is important for the disease," said Virginia Lee, a professor of pathology and laboratory medicine at the University of Pennsylvania School of Medicine, in Philadelphia.

The results were published in the Feb. 28 online edition of Science.

ALS, also known as Lou Gehrig's disease, is an incurable motor neuron disorder that affects some 30,000 Americans, according to the ALS Association. From 5 percent to 10 percent of those cases are inherited; the remainder are sporadic. Several genes have been associated with the disease, most notably SOD1, which accounts for about 20 percent of familial cases and 3 percent of sporadic ones.

The gene in the present study, TARDBP, encodes TDP-43, a gene involved in, among other things, RNA processing. In 2006, Lee's group discovered that TDP-43 is a pivotal gene in both ALS and a cognitive disorder called frontotemporal lobar dementia (FTLD).

The question was, were these TDP-43 mutations involved in disease pathology or merely a byproduct of it?

"What we needed was a 'smoking gun,' " said Lee."Can we find mutations in TDP-43 in ALS patients?"

Dr. Christopher Shaw, a professor of neurology and neurogenetics at King's College London, led an international team of researchers to find out.

Shaw studied the TDP-43 gene in 154 families with familial ALS. They discovered one family with a mutation in the gene, which was present in all affected family members, and absent in unaffected ones. The mutation changes just a single amino acid in the protein sequence. The team also found similar TDP-43 mutations in two additional, sporadic cases.

But merely finding a mutant gene in affected individuals does not automatically mean it causes disease. What is needed is proof these mutations induce a neurological disease akin to ALS. To address that question, the team expressed both normal and mutant TDP-43 in chick embryos.

"Much to our surprise, in 49 of 49 embryos [expressing the mutant TDP-43], chick spinal cord cells died, while if we injected the [normal] gene, we saw no death at all," said Shaw. "That tells us this tiny change in the gene is harmful. This isn't just an innocent variation, there is something the variation is doing that is harmful to cells."

"I think it's a very, very exciting finding," Lee said, especially in light of the recent publication in the Annals of Neurology of another case of familial ALS with a mutation in TDP-43.

Dr. Catherine Lomen-Hoerth, director of the ALS Center at the University of California, San Francisco, said the findings could aid ALS research and drug development.

"For a long time, we've only had one good genetic mouse model for the disease," she said, referring to the SOD1-based model. "I think this discovery provides the possibility of making a mouse model that might be very helpful to help understand both ALS and FTLD."

The two diseases "may represent opposite ends of a spectrum of the same disease," Lee explained.

Most ALS cases (except those caused by SOD1 mutations) exhibit TDP-43 mutations, Shaw said. Yet mutations in the gene appear to be relatively rare, at least based on their prevalence in the current study. What these latest findings do is provide "the first concrete link" between TDP-43 and disease pathology.

The situation is analogous to Alzheimer's Disease, he said, which is associated with beta-amyloid protein accumulation. Though relatively few Alzheimer's cases are actually caused by mutations in the amyloid protein gene, their discovery underscored the protein's role in disease pathology.

"It gives us a biochemical tool to recapitulate the disease process in animals, to begin to develop treatments," Shaw said. "And so, it is a really crucial weapon against the disease."

More information

For more on amyotrophic lateral sclerosis, visit the ALS Association.



SOURCES: Christopher Shaw, M.D., Ph.D., professor, neurology and neurogenetics, King's College London; Catherine Lomen-Hoerth, M.D., Ph.D., associate professor, neurology, and director, ALS Center, University of California, San Francisco; Virginia Lee, Ph.D., professor, pathology & laboratory medicine, University of Pennsylvania School of Medicine, Philadelphia; Feb. 28, 2008, Sciencexpress online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Treatment for disease that affects estimated 1 in 2000 children gets them to eat again
2. Specialized Care Essential for Women With Congenital Heart Disease Undergoing Pregnancy
3. Race, insurance status affect access to transplantation and kidney disease treatment
4. Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease?
5. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
6. Adult Stem Cells Help Those With Immune Disorders, Heart Disease
7. Childrens Hospital 1 of 10 pediatric hospitals in US selected to study liver disease in kids
8. The human and economic cost of heart disease in Europe
9. Laser Screen Detects Diseases in Breath
10. USAID Fights Neglected Tropical Diseases
11. Heart Disease Deaths Over-Reported in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Gene for Lou Gehrig's Disease Identified
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: